Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

134.02
Delayed Data
As of 4:00pm ET
 +2.81 / +2.14%
Today’s Change
60.30
Today|||52-Week Range
134.97
+33.66%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$24.9B

Company Description

Incyte Corp. is a biopharmaceutical company, which focuses on the discovery, development, development, formulation, manufacturing and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. Its product, Jakafi, a JAK1 and JAK2 inhibitor, is currently approved in the U.S. for the treatment of intermediate or high-risk myelofibrosis and is in development as a potential treatment for other cancers. The companywas founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Contact Information

Incyte Corp.
1801 Augustine Cut-Off
Wilmington Delaware 19803
P:(302) 498-6700
Investor Relations:
(302) 498-5914

Employees

Shareholders

Mutual fund holders53.75%
Other institutional45.93%
Individual stakeholders16.00%

Top Executives

Hervé HoppenotChairman, President & Chief Executive Officer
David W. GryskaChief Financial Officer & Executive Vice President
Reid M. HuberChief Scientific Officer & Executive VP
Steven H. SteinChief Medical Officer & Senior Vice President
Eric H. SiegelSecretary, Executive VP & General Counsel